RayKnowChina Research Map
Shortlist0

Jilin University

吉林大学

ChangchunUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.1%Leads under 1 in 100 of China's research papers on NPC ▼ from 0.7%

Led 3 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025
ThemesImaging & AIRadiotherapy techniqueSide effects & quality of life

Hospitals counted here

  1. First Hospital of Jilin University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. Continual source-free active domain adaptation for nasopharyngeal carcinoma tumor segmentation across multiple hospitals.2025Neural networks : the official journal of the International Neural Network Society
  2. Research progress on mechanism and imaging of temporal lobe injury induced by radiotherapy for head and neck cancer.2022European radiology
  3. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Trials on ClinicalTrials.gov1
  1. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.2%Leads under 1 in 100 of China's research papers on ESCC

Led 7 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025
ThemesImmunotherapySurgeryImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Hospital of Jilin University5
  2. Second Hospital of Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A nomogram to predict long-term survival after resection for esophageal cancer: An observational study in northeast China.2025Surgery
  2. Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit.2022Frontiers in immunologyFree full text
  3. FSCN1 regulates TGF-β signalling to promote esophageal squamous cell carcinoma metastasis via stabilizing THBS1 mRNA.2025Communications biologyFree full text
  4. FBXO10 inhibits ferroptosis and promotes the progression of esophageal squamous cell carcinoma by post-translational mediation of ACSL4 degradation.2025Journal of molecular histology
  5. Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.2023Cancer biology & therapyFree full text
Trials on ClinicalTrials.gov6
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  2. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  3. A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT03958890Study sitePhase 3Start 2019-06
  4. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  5. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  6. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03817567Study sitePhase 1/Phase 2Start 2018-07

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.9%Leads under 1 in 100 of China's research papers on HCC ▼ from 1.5%

Led 135 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
135
Trials it led
3
Share of China's trials
0.2%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 222025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Hospitals counted here

  1. First Hospital of Jilin University76
  2. China-Japan Union Hospital, Jilin University20
  3. Second Hospital of Jilin University15
  4. Japan Union Hospital, Jilin University Counted in the group total1
  5. Jilin University Second Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification.2023GutFree full text
  2. Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses.2023Journal of hepatology
  3. cFUT8 promotes liver cancer progression by miR-548c/FUT8 axis.2021Signal transduction and targeted therapyFree full text
  4. Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  5. Predictive value of peripheral blood CD4+ T and NK cells on efficacy and long-term survival in advanced HCC patients receiving immunotherapy.2025Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment DecisionsNot yet recruitingNCT07582419Lead sponsorStart 2026-04
  2. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  3. Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)RecruitingNCT07331883Study sitePhase 2Start 2025-11
  4. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  5. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  6. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.0%Leads under 1 in 100 of China's research papers on Stomach cancer ▼ from 1.7%

Led 97 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
7
Research papers it led
97
Trials it led
16
Share of China's trials
1.1%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 4420242025: 002025
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsEarly detection & endoscopy

Hospitals counted here

  1. First Hospital of Jilin University41
  2. China-Japan Union Hospital, Jilin University21
  3. Second Hospital of Jilin University17
  4. Japan Union Hospital, Jilin University Counted in the group total1
  5. Union Hospital, Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The effectiveness of health education based on the 5Ts for teach-back on oral nutritional supplements compliance of post-discharge patients after surgery for gastric cancer: a randomized controlled trial.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCTFree full text
  2. Lung enteric-type adenocarcinoma with gastric metastasis: a rare case report and literature review.2024Frontiers in immunologyFree full text
  3. A case of malignant gastric glomus tumor and literature review: A case report.2024MedicineFree full text
  4. A case of gastric granulosa cell tumor resected by endoscopic submucosal dissection.2024Zeitschrift fur Gastroenterologie
  5. Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.2024BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric CancerRecruitingNCT07615374Lead sponsorN/AStart 2026-05
  2. The PRE-VAIL StudyRecruitingNCT07176624Lead sponsorN/AStart 2025-09
  3. PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal CancerNot yet recruitingNCT07031011Lead sponsorPhase 1Start 2025-06
  4. Distribution Characteristics of Helicobacter PyloriRecruitingNCT07253948Lead sponsorStart 2025-10
  5. The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric CancerRecruitingNCT06881043Lead sponsorStart 2024-11
  6. Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer SurgeryRecruitingNCT07119463Lead sponsorPhase 2Start 2024-10

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Hepatoblastoma ▼ from 3.5%

Led 1 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Hospital of Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Incidence trends and a nomogram for predicting overall survival in children with hepatoblastoma: A population-based analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.3%Leads about 1 in 75 of China's research papers on Retinoblastoma ▼ from 4.0%

Led 4 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of Jilin University3
  2. Second Hospital of Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.9%Leads about 1 in 51 of China's research papers on Osteosarcoma ▼ from 3.9%

Led 44 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
44
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Hospital of Jilin University17
  2. China-Japan Union Hospital, Jilin University13
  3. Second Hospital of Jilin University10
  4. Second Norman Bethune Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Primary extraskeletal osteosarcoma of rectal mesentery: a rare case and literature review.2025World journal of surgical oncology
  2. Invasive spindle-cell rhabdomyosarcoma with osteolysis in a dog: case report and literature review.2023Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  3. Breast osteosarcoma originating from a malignant phyllodes tumor: A case report of a rare neoplasm.2021Medicine
  4. Multifunctional poly(amino acid) nanomedicine modulates macrophage polarization for osteosarcoma immunotherapy.2026Journal of controlled release : official journal of the Controlled Release Society
  5. Nanotechnology-Driven Strategies in Osteosarcoma Advances in Treatment: Immunotherapy and Drug Delivery.2025International journal of nanomedicine

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.4%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour ▼ from 1.0%

Led 2 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Second Hospital of Jilin University1
  2. China-Japan Union Hospital, Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.0%Leads under 1 in 100 of China's research papers on Neuroblastoma ▼ from 2.6%

Led 11 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

Hospitals counted here

  1. First Hospital of Jilin University7
  2. Second Hospital of Jilin University1
  3. China-Japan Union Hospital, Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma ▼ from 4.8%

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of Jilin University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.5%Leads about 1 in 67 of China's research papers on Myeloma

Led 25 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
4
Research papers it led
25
Trials it led
6
Share of China's trials
1.2%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance

Hospitals counted here

  1. First Hospital of Jilin University17
  2. China-Japan Union Hospital, Jilin University4
  3. Second Hospital of Jilin University4
  4. Orthopaedic Medical Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Development and validation of a prognostic staging system for primary plasma cell leukemia.2025Journal of hematology & oncologyFree full text
  2. Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.2025Blood reviews
  3. Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis.2024Clinical medicine (London, England)Free full text
  4. Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.2024Journal of hematology & oncologyFree full text
  5. Diagnostic value of WB-DWI versus 18F-FDG PET/CT for the detection of multiple myeloma.2023Indian journal of cancer
Trials on ClinicalTrials.gov6
  1. Risk-adapted Therapeutic Strategy in +1q NDMMNot yet recruitingNCT07045168Lead sponsorStart 2025-09
  2. IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell LeukemiaRecruitingNCT07509086Lead sponsorPhase 2Start 2025-12
  3. Dara-PD in the Treatment of Patients With First Relapse of Multiple MyelomaRecruitingNCT06252792Lead sponsorStart 2023-06
  4. Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMMRecruitingNCT06099912Lead sponsorStart 2021-09
  5. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  6. 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Study sitePhase 2/Phase 3Start 2025-12

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.0%Leads none of China's research papers on B-ALL

Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.5%Leads under 1 in 100 of China's research papers on Aplastic anaemia New since 2021

Led 2 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025
ThemesImmunosuppressive treatmentThrombopoietin drugs

Hospitals counted here

  1. First Hospital of Jilin University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
1.0%Leads about 1 in 100 of China's research papers on HLH

Led 4 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025
ThemesEBV & infection triggersChildrenDiagnosis & prognosis

Hospitals counted here

  1. First Hospital of Jilin University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征
7.4%Leads about 1 in 13 of China's research papers on Atypical haemolytic uraemic syndrome

Led 2 of 27 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (11.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Hospital of Jilin University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
2.9%Leads about 1 in 35 of China's research papers on NMOSD ▼ from 4.9%

Led 14 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 0020242025: 002025
ThemesAntibodies & diagnosisAcute attack treatmentImaging

Hospitals counted here

  1. First Hospital of Jilin University11
  2. China-Japan Union Hospital, Jilin University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
2.9%Leads about 1 in 35 of China's research papers on IgG4-RD ▲ from 2.0%

Led 7 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025
ThemesDiagnosis & look-alikesKidney, retroperitoneum & vesselsHead, eye socket & salivary glands

Hospitals counted here

  1. Second Hospital of Jilin University5
  2. Jilin University Second Hospital1
  3. China-Japan Union Hospital, Jilin University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.6%Leads under 1 in 100 of China's research papers on Myasthenia gravis ▼ from 2.9%

Led 3 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 002025
ThemesThymus & thymectomyAntibodies & diagnosis

Hospitals counted here

  1. China-Japan Union Hospital, Jilin University2
  2. First Hospital of Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.7%Leads about 1 in 59 of China's research papers on Moyamoya ▼ from 3.1%

Led 6 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesImaging & blood flowChildrenRevascularisation surgery

Hospitals counted here

  1. First Hospital of Jilin University4
  2. China-Japan Union Hospital, Jilin University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
1.0%Leads about 1 in 100 of China's research papers on Wilson disease New since 2021

Led 2 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025
ThemesGenetics (ATP7B)Treatment (chelation, zinc)Diagnosis & copper tests

Hospitals counted here

  1. First Hospital of Jilin University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.9%Leads about 1 in 53 of China's research papers on Anti-NMDA receptor encephalitis

Led 5 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of Jilin University5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.1%Leads about 1 in 93 of China's research papers on Takayasu arteritis ▼ from 2.2%

Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. First Hospital of Jilin University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.9%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 9 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 3320232024: 0020242025: 112025

Hospitals counted here

  1. Second Hospital of Jilin University7
  2. China-Japan Union Hospital, Jilin University1
  3. First Hospital of Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.6%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 5 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 3320242025: 002025

Hospitals counted here

  1. Second Hospital of Jilin University2
  2. First Hospital of Jilin University2
  3. China-Japan Union Hospital, Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
1.4%Leads about 1 in 73 of China's research papers on Fabry disease ▼ from 13.6%

Led 1 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.6%Leads about 1 in 61 of China's research papers on Behçet disease

Led 4 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. First Hospital of Jilin University3
  2. Second Hospital of Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led4
  1. OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS OVER TIME IN BEHÇET'S UVEITIS.2023Retina (Philadelphia, Pa.)
  2. Recurrent aortic-arch pseudoaneurysm eroding into the left main bronchus following descending thoracic aortic stent repair.2023Journal of cardiothoracic surgery
  3. Long-segment diffuse cervical spinal cord involvement as the first episode of neuro-Behçet's disease: a case report.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Association between IL1B -511C/T polymorphism and Behçet's disease: a meta-analysis.2021The Journal of international medical research
Trials on ClinicalTrials.gov1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.9%Leads about 1 in 53 of China's research papers on IgA nephropathy ▼ from 2.6%

Led 14 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
1
Research papers it led
14
Trials it led
1
Share of China's trials
0.9%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Second Hospital of Jilin University7
  2. First Hospital of Jilin University7

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
4.7%Leads about 1 in 21 of China's research papers on Primary biliary cholangitis ▼ from 6.7%

Led 14 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. First Hospital of Jilin University11
  2. Second Hospital of Jilin University2
  3. China-Japan Union Hospital, Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Progress and Perspectives in Overlapping Primary Biliary Cholangitis and Autoimmune Hepatitis: A Comprehensive Review.2025Journal of gastrointestinal and liver diseases : JGLD
  2. The Albumin-Bilirubin Score as a Predictor of Liver-Related Mortality in Primary Biliary Cholangitis with Compensated Cirrhosis.2023Digestive diseases (Basel, Switzerland)
  3. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  4. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome in a patient with paroxysmal nocturnal hemoglobinuria: a case report.2021The Journal of international medical research
  5. Causal association between type 1 diabetes and autoimmune cholestasis: A bi-directional Mendelian randomized study.2025International journal of immunopathology and pharmacology
Trials on ClinicalTrials.gov6
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  3. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08
  4. Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)Status unknownNCT04956328Study sitePhase 3Start 2021-07
  5. Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary CirrhosisCompletedNCT06715319Study sitePhase 3Start 2021-10
  6. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisActive, not recruitingNCT05050136Study sitePhase 2Start 2021-09

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary sclerosing cholangitis ▼ from 4.1%

Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. China-Japan Union Hospital, Jilin University1
  2. First Hospital of Jilin University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov